Celldex Therapeutics Inc. (CLDX)’s Market Momentum: Closing Strong at 32.76, Down -2.12

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Celldex Therapeutics Inc.’s stock clocked out at $32.76, down -2.12% from its previous closing price of $33.47. In other words, the price has decreased by -$2.12 from its previous closing price. On the day, 1.0 million shares were traded. CLDX stock price reached its highest trading level at $33.295 during the session, while it also had its lowest trading level at $32.28.

Ratios:

To gain a deeper understanding of CLDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 31.77 and its Current Ratio is at 31.77. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

On November 10, 2023, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $27.

On August 22, 2023, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $21.Wells Fargo initiated its Underweight rating on August 22, 2023, with a $21 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 30 ’24 when Heath-Chiozzi Margo sold 38,719 shares for $34.07 per share. The transaction valued at 1,319,156 led to the insider holds 7,094 shares of the business.

Crowley Elizabeth sold 38,597 shares of CLDX for $1,298,384 on May 30 ’24. The SR. VP & CPDO now owns 9,074 shares after completing the transaction at $33.64 per share. On May 30 ’24, another insider, Martin Samuel Bates, who serves as the SVP AND CFO of the company, sold 35,000 shares for $34.05 each. As a result, the insider received 1,191,774 and left with 25,128 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 2159227904 and an Enterprise Value of 1337497600. For the stock, the TTM Price-to-Sale (P/S) ratio is 355.72 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 220.273 whereas that against EBITDA is -9.091.

Stock Price History:

Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.11. The 50-Day Moving Average of the stock is -15.92%, while the 200-Day Moving Average is calculated to be -5.91%.

Shares Statistics:

It appears that CLDX traded 757.17K shares on average per day over the past three months and 674860 shares per day over the past ten days. A total of 65.91M shares are outstanding, with a floating share count of 64.39M. Insiders hold about 2.30% of the company’s shares, while institutions hold 104.83% stake in the company. Shares short for CLDX as of 1715731200 were 6615448 with a Short Ratio of 8.74, compared to 1713139200 on 6749943. Therefore, it implies a Short% of Shares Outstanding of 6615448 and a Short% of Float of 11.62.

Most Popular